Lighthouse International Response To JAMA Article On Common Genetic Variants Associated With Progression In Advanced Forms Of AMD
"While we have known for many years that smoking and being overweight contribute to the risk of macular degeneration, the findings of a genetic link for the progression of macular degeneration from early or intermediate stages to advanced disease are indeed significant and will have a major impact on future study and possible treatment of AMD.
These findings will be particularly important for the 13-15 million Americans who are pre-symptomatic for macular degeneration.
For the six million Americans who have macular degeneration, it is critical to note that there are steps they can take. People with the disease can seek medical treatment, as well as low vision care and vision rehabilitation. These services often include the prescription of optical devices, which can maximize remaining vision. Ninety percent of macular degeneration patients have the dry form and can significantly benefit from vision rehabilitation, but rehabilitation is often overlooked as one of the major treatment modalities, along with FDA-approved treatment and antioxidants," says Bruce P. Rosenthal, OD, FAAO, and Chief of the Low Vision Clinical Practice at Lighthouse International. Dr. Rosenthal is one of the leading international experts on vision loss from diseases such as AMD.
Founded in 1905, Lighthouse International is a leading non-profit organization dedicated to preserving vision and to providing critically needed health care services to help people of all ages overcome the challenges of vision loss. Through services, education, research and advocacy, the Lighthouse enables people with low vision and blindness to enjoy safe, independent and productive lives. For more information about vision loss, its causes and what you can do about it, contact Lighthouse International at 1-800-829-0500 or visit www.lighthouse.org